PitchSend

Investor Presentaiton

India (Rx + Gx): Second consecutive quarter of 13%+ growth in India prescription; Trade Gx comes back to YoY growth India prescription 14% YOY India Trade Gx 7% YOY Q3 Y-o-Y Rs Cr 1777 1577 13% Q3 FY 19 Q3 FY 20 Q3 Q-o-Q Rs Cr 1730 3% 1777 Q2 FY20 Q3 FY20 Cipla Therapy Market Rank Market Share Cipla Market Growth Growth Overall Chronic Respiratory Inhalation 2 7.85% 13% 11% 1 68% 14% 12% Urology 1 14.5% 12% 14% Cardiology 4 5.6% 14% 11% Trade generics business delivered growth of 7% on a year on year basis The prescription business grew 14% on a YoY basis driven by performance across both chronic and acute therapies. Key Business Highlights¹ Continued growth investments: Acquired Vysov and in-licensed Elores brands, Berok Zindagi 2 on-going Investor Presentation: Q3FY20 1.Market data as per IQVIA MAT Dec' 19 7

View entire presentation